Press release

Press release

October 1, 2015

Follicum’s patent preliminary approved

Follicum has received a preliminary approval – a so called “Intention to Grant” – by the European Patent Office (EPO) regarding the company’s patent application for stimulation of hair growth. To read the full press release (in Swedish) please click here. For more information about Follicum’s research results, please contact: Jan Alenfall, CEO Tel +46 (0)46 19 21 […]

September 9, 2015

Cooperation initiated with research group in Berlin for the planned clinical study

As previously communicated, Follicum’s intention is to start a clinical phase I/IIa study around year-end 2015/early 2016. We can now announce that a cooperation with the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin, Germany, has been initiated regarding our planned clinical phase I/IIa study. Follicum’s intention is to submit an application […]

September 1, 2015

Follicum has completed toxicity studies

Follicum announced in March 2015  that they had started two larger toxicity studies to  add information to the two short time toxicity studies and  continue development. The short time studies were finalized in February 2015, and showed no adverse effects. The two larger toxicity studies have now been finished according to plan, showing very promising […]

August 25, 2015

Drug substance ready for production

Follicum announce today that the synthesis of the peptide has been completed.  The peptide is the active ingredient of the product planned to be used in the clinical Phase I/IIa study. Production of product for the clinical Phase I/IIa study Follicum announced in early June that the company had signed an agreement with the peptide […]

August 21, 2015

Half-year Report 2015

Follicum’s half-year report 2015 (1 January to 30 June) is now published. Click here to open the report (in Swedish).

June 11, 2015

Demo Press Release

Follicum can today announce that an agreement has been signed with PolyPeptide Group and Recipharm AB prior to the clinical study, which is expected to start around the turn of the year 2015/2016. Read more here.